Plain-English translation of NCT06084806 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging agent called [18F]F-AraG that can visualize activated immune cells in the body using PET scans. Researchers want to see if this scan can reliably detect how your immune system is fighting cancer before you start immunotherapy treatment. The goal is to develop a better tool to predict whether immunotherapy will work for you.
Current imaging scans show tumor size but don't capture how the immune system is responding to treatment—which is crucial for immunotherapy. This medication was designed to light up active immune cells, potentially giving doctors a clearer picture of treatment effectiveness earlier than traditional scans.
You likely qualify if…
You likely don't qualify if…
You will come in for two PET/CT imaging scans within 7 days of each other, before you begin any immunotherapy treatment. During each scan, you will receive an injection of the imaging agent and then lie still in the scanner for imaging. The scans help researchers understand whether this new imaging method can reliably detect immune activity in your body.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States